Compare FOLD & HHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOLD | HHH |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.0B |
| IPO Year | 2007 | N/A |
| Metric | FOLD | HHH |
|---|---|---|
| Price | $14.36 | $81.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $27.56 | ★ $90.00 |
| AVG Volume (30 Days) | ★ 21.4M | 410.3K |
| Earning Date | 02-18-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 234.52 |
| EPS | N/A | ★ 5.10 |
| Revenue | $598,704,000.00 | ★ $1,834,033,000.00 |
| Revenue This Year | $21.49 | N/A |
| Revenue Next Year | $18.46 | $19.38 |
| P/E Ratio | ★ N/A | $15.98 |
| Revenue Growth | 21.28 | ★ 69.81 |
| 52 Week Low | $5.51 | $61.41 |
| 52 Week High | $14.36 | $91.07 |
| Indicator | FOLD | HHH |
|---|---|---|
| Relative Strength Index (RSI) | 89.94 | 49.55 |
| Support Level | $14.26 | $80.95 |
| Resistance Level | $14.35 | $82.97 |
| Average True Range (ATR) | 0.05 | 1.50 |
| MACD | -0.12 | 0.37 |
| Stochastic Oscillator | 100.00 | 75.14 |
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.